ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
185.6 EUR
+3.2 (+1.75%)
4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. While 4AB is still in line with the averages on profitability rating, there are concerns on its financial health. 4AB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- 4AB had positive earnings in the past year.
- 4AB had a positive operating cash flow in the past year.
- 4AB had positive earnings in each of the past 5 years.
- 4AB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- 4AB's Return On Assets of 1.75% is fine compared to the rest of the industry. 4AB outperforms 75.58% of its industry peers.
- 4AB has a better Return On Invested Capital (15.64%) than 94.19% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for 4AB is above the industry average of 11.58%.
- The last Return On Invested Capital (15.64%) for 4AB is above the 3 year average (13.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
- 4AB has a Profit Margin of 3.94%. This is in the better half of the industry: 4AB outperforms 77.91% of its industry peers.
- 4AB's Profit Margin has declined in the last couple of years.
- 4AB's Operating Margin of 33.05% is amongst the best of the industry. 4AB outperforms 89.53% of its industry peers.
- In the last couple of years the Operating Margin of 4AB has declined.
- 4AB has a Gross Margin of 71.16%. This is in the better half of the industry: 4AB outperforms 62.79% of its industry peers.
- 4AB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 4AB is creating value.
- The number of shares outstanding for 4AB remains at a similar level compared to 1 year ago.
- The number of shares outstanding for 4AB has been increased compared to 5 years ago.
- 4AB has a worse debt/assets ratio than last year.
2.2 Solvency
- 4AB has an Altman-Z score of 2.35. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.35, 4AB is in the better half of the industry, outperforming 69.77% of the companies in the same industry.
- The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.49, 4AB belongs to the top of the industry, outperforming 82.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.35 |
ROIC/WACC1.86
WACC8.42%
2.3 Liquidity
- A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
- 4AB has a Current ratio of 0.72. This is in the lower half of the industry: 4AB underperforms 76.74% of its industry peers.
- A Quick Ratio of 0.60 indicates that 4AB may have some problems paying its short term obligations.
- The Quick ratio of 4AB (0.60) is worse than 76.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
- The earnings per share for 4AB have decreased strongly by -12.09% in the last year.
- Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
- 4AB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.40%.
- Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
- 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
- Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 23.03, which indicates a rather expensive current valuation of 4AB.
- Based on the Price/Earnings ratio, 4AB is valued cheaper than 82.56% of the companies in the same industry.
- 4AB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.94.
- A Price/Forward Earnings ratio of 14.98 indicates a correct valuation of 4AB.
- 90.70% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (23.94), we can say 4AB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.03 | ||
| Fwd PE | 14.98 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than the industry average as 79.07% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, 4AB is valued cheaply inside the industry as 86.05% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.54 | ||
| EV/EBITDA | 15.64 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 4AB does not grow enough to justify the current Price/Earnings ratio.
- 4AB has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.87% in the coming years.
PEG (NY)3.15
PEG (5Y)9.17
EPS Next 2Y19.85%
EPS Next 3Y16.87%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 3.19%, 4AB has a reasonable but not impressive dividend return.
- 4AB's Dividend Yield is rather good when compared to the industry average which is at 0.75. 4AB pays more dividend than 96.51% of the companies in the same industry.
- 4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
5.2 History
- The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
- 4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
FRA:4AB (1/21/2026, 4:44:59 PM)
185.6
+3.2 (+1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap328.03B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target213.08 (14.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
Yearly Dividend5.38
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.08%
PT rev (3m)8.41%
EPS NQ rev (1m)-3.35%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.03 | ||
| Fwd PE | 14.98 | ||
| P/S | 6.45 | ||
| P/FCF | 19.54 | ||
| P/OCF | 18.44 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.64 |
EPS(TTM)8.06
EY4.34%
EPS(NY)12.39
Fwd EY6.68%
FCF(TTM)9.5
FCFY5.12%
OCF(TTM)10.06
OCFY5.42%
SpS28.77
BVpS-1.27
TBVpS-44.67
PEG (NY)3.15
PEG (5Y)9.17
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.35 |
F-Score7
WACC8.42%
ROIC/WACC1.86
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status for 4AB stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for 4AB stock?
The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.
How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.